cck-a

CCK-A receptor inhibitor 1 是一种有效的缩胆囊素 A (CCK-A) 受体抑制剂(IC50：340 nM）。CCK-A receptor inhibitor 1 可用于研究与消化系统相关的疾病。

N-Cbz-DL-tryptophan 是一种胆囊收缩素受体拮抗剂，可消除离体心脏对 CCK-8 的反应。

Proglumide (Binoside) 是一种非肽的、口服具有活性的胆囊收缩素(CCK)-A B 受体拮抗剂。它能够选择性阻断 CCK 在中枢神经系统中的作用。它能够抑制胃分泌，具有保护胃十二指肠粘膜的能力，并表现出抗癫痫和抗氧化活性。

(Iso)-FK-480 是一种新型可口服的胆囊收缩素 A（CCK-A）拮抗剂，可用于研究治疗慢性胰腺炎。

CCK Octapeptide, non-sulfated acetate 是一种合成的胆囊收缩素脱硫酸肽。

Itriglumide (CR-2945) 是一种胆囊收缩素 （CCK）-2 受体拮抗剂，具有抗分泌和抗溃疡作用。

[D-Arg1,D-Phe5,D-Trp7,9,Leu11]-Substance P acetate ([D-Arg1,D-Phe5,D-Trp7,9,Leu11]-Substance P acetate (96736-12-8 free base)) 是广谱神经肽反向激动剂和拮抗剂。 ghrelin 受体的强效完全反向激动剂(EC50 = 5.2 nM)；减少组成型生长素释放肽受体信号传导。它也是速激肽、缓激肽、CCK 和铃蟾肽受体的拮抗剂。在体外诱导细胞凋亡并抑制癌细胞生长。

A-65186 是一种选择性A型谷氨酸基胆囊收缩素 （CCK） 拮抗剂，可用于研究炎症和胃肠道损伤。

Sincalide (CCK-8) 是一种速效的胆囊收缩素的氨基酸多肽激素类似物，可在胆囊造影术中静脉使用。它的肝胆生理作用是增加胆汁的分泌，使胆囊收缩并使 Oddi 的括约肌松弛，从而使胆汁排入十二指肠。它是一种通过注射促进胆囊收缩并帮助诊断胆囊和胰腺疾病的药物。

WAY-620645 是一种 CCK 拮抗剂，具有抗肿瘤和镇痛活性。

Nastorazepide 是一种选择性的、口服有效的1,5-苯并二氮杂环衍生物胃泌素 胆囊收缩素2（CCK-2）受体拮抗剂，具有抗肿瘤的潜能。

CCK (26-31) is an N-terminal fragment of CCK , a peptide hormone found in the intestine and brain that stimulates digestion, mediates satiety, and is involved in anxiety.

CCK (26-30) is an N-terminal fragment of CCK , a peptide hormone found in the intestine and brain that stimulates digestion, mediates satiety, and is involved in anxiety. The sulfated form of CCK (26-30) inhibits binding of [125I]CCK-33 to guinea pig cortical membranes by 10% when used at a concentration of 0.1 mM.

Ksg 504 has superior selectivity and affinity to CCK-A receptors and derived from proglumide.

Pinolenic acid is a polyunsaturated fatty acid found in Korean pine (Pinus orientalis) and maritime pine (Pinus pinaster) seed oils. Both oils have been found to have lipid-lowering properties. A diet containing maritime pine seed oil (MPSO) lowered high-density lipoprotein and ApoA1 levels in transgenic mice expressing human ApoA1. MPSO was found to diminish cholesterol efflux in vitro. Korean pine seed oil supplements may help in obesity by reduction of appetite. People taking this oil had an increase in the satiety hormones CCK and GLP-1 and a reduced desire to eat. The activity of the oil is attributed to pinolenic acid. Pinolenic acid is not converted to arachidonic acid metabolically and can reduce arachidonic acid levels in the phosphatidylinositol fraction of HepG2 cells from 15.9% to 7.0%. Pinolenic acid ethyl ester is a neutral, more lipophilic form of the free acid.

BC 197 is a selective CCK-B agonist.

A71378 is a high potency, selectivity CCK-A receptors agonist.

Proglumide hemicalcium is a antagonist of nonpeptide and orally active cholecystokinin (CCK)-A/B receptors, has antiepileptic and antioxidant activities.

L-365260 hemihydrate 是选择性的、具有口服活性的非肽胃泌素和脑胆囊收缩素受体 (CCK-B) 拮抗剂，Kis 值分别为 1.9 nM 和 2.0 nM。L-365260 hemihydrate 以竞争性方式与豚鼠胃泌素和脑 CCK 受体相互作用。

CCK-B Receptor Antagonist 1 is a cholecystokinin B (CCK-B) receptor agonist and has the potential of reducing the secretion of gastric acid.

A70874 has high selectivity and potency for cholecystokinin (CCK) a receptor.

Tarazepide is a potent and specific antagonist of CCK-A receptor.

Cholecystokinin Octapeptide, desulfated TFA, is a synthetic octapeptide derived from Cholecystokinin (CCK) that has undergone desulfation.

CCK (27-33) is a C-terminal fragment of CCK , a peptide hormone found in the intestine and brain that stimulates digestion, mediates satiety, and is involved in anxiety. Non-sulfated CCK (27-33) inhibits binding of [3H]naloxone in rat cerebellum membranes (IC50 = 4 uM) and inhibits electrically-stimulated contraction of isolated guinea pig ileum (IC50 = 17 uM), an effect that can be reversed by naloxone. Unlike sulfated CCK (27-33), the non-sulfated form does not reduce exploratory behavior in mice when administered at doses up to 1 uMol/kg.

Pbc 264 is a CCK agonist.

L 365031 is a CCK antagonist.

Cholecystokinin (27-32)-amide is a CCK receptor antagonist.

CI-1015 is a CCK-B receptor antagonist with oral activity.

Fpl 14294 is a novel CCK-8 agonist with effective intranasal anorectic activity in the rat.

Jmv 180, a CCK analog, can distinguish high-affinity cholecystokinin receptors from low-affinity cholecystokinin receptors.

Gastrin/CCK antagonist 1 是一种有效的 gastrin/CCK 拮抗剂，可用于研究代谢系统相关疾病。

Cholecystokinin-33 (swine) 是胆囊收缩素 (CCK) 片段，可以减少食物摄入量和胆囊收缩。

V-9-M Cholecystokinin nonapeptide (Prepro CCK Fragment V-9-M) 是胆囊收缩素(CCK)的前体化合物。胆囊收缩素(CCK)是一种刺激胆囊收缩和胰腺外分泌的脑肠肽，可从狗和猫的小肠中提取的，可以引起胆囊收缩。

Cholecystokinin type B receptor antagonist PD-136,450 is a partial secretory agonist in the stomach and a full agonist in the pancreas of the rat. Gastrin (cholecystokinin type B (CCK-B)) receptor antagonists may help to elucidate the physiological role o

Givinostat (ITF-2357) is a HDAC inhibitor with an IC50 of 198 and 157 nM for HDAC1 and HDAC3, respectively. Givinostat (ITF2357) suppresses total LPS-induced IL-1β production robustly compared with the reduction by ITF3056. At 25, 50, and 100 nM, Givinostat reduced IL-1β secretion more than 70%. Givinostat (ITF-2357) suppresses the production of IL-6 in PBMCs stimulated with TLR agonists as well as the combination of IL-12 plus IL-18. IL-6 secretion decreases to 50% at 50 nM Givinostat, but at 100 and 200 nM, there is no reduction[1]. As shown by the CCK-8 assay, Givinostat (ITF-2357) inhibits JS-1 cell proliferation in a concentration-dependent manner. Treatment with Givinostat ≥500 nM is associated with significant inhibition of JS-1 cell proliferation (P<0.01). Also, the cell inhibition rate significantly differs between the group cotreated with Givinostat ≥250 nM plus LPS and the group without LPS treatment (same Givinostat concentration) (P<0.05)[2]. Givinostat (ITF2357) at 10 mg kg is used as a positive control and, as expected, reduced serum TNFα by 60%. Strikingly, pretreatment of ITF3056 starting at 0.1 mg kg significantly reduces the circulating TNFα by nearly 90%. To achieve a significant increase in serum IL-1β production, a higher dose of LPS is injected (10 mg kg), and blood is collected after 4 h. Similarly, when pretreated with lower doses of Givinostat (ITF-2357) (1 or 5 mg kg), there is a 22% reduction for 1 mg kg and 40% for 5 mg kg[1]. [1]. Li S, et al. Specific inhibition of histone deacetylase 8 reduces gene expression and production of proinflammatory cytokines in vitro and in vivo. J Biol Chem. 2015 Jan 23;290(4):2368-78. [2]. Wang YG, et al. Givinostat inhibition of hepatic stellate cell proliferation and protein acetylation. World J Gastroenterol. 2015 Jul 21;21(27):8326-39. [3]. Leoni F, et al. The histone deacetylase inhibitor ITF2357 reduces production of pro-inflammatory cytokines in vitro and systemic inflammation in vivo. Mol Med. 2005 Jan-Dec;11(1-12):1-15.

PD-149164 is an agonist of the CCK-A receptor.

Pinolenic acid is a polyunsaturated fatty acid found in Korean pine (Pinus orientalis) and maritime pine (Pinus pinaster) seed oils. Both oils have been found to have lipid-lowering properties. A diet containing maritime pine seed oil (MPSO) lowered HDL and ApoA1 levels in transgenic mice expressing human ApoA1. MPSO was found to diminish cholesterol efflux in vitro.[1] Korean pine seed oil supplements may help in obesity by reduction of appetite. People taking this oil had an increase in the satiety hormones CCK and GLP-1 and a reduced desire to eat.[2] The activity of the oil is attributed to pinolenic acid. Pinolenic acid is not converted to arachidonic acid metabolically and can reduce arachidonic acid levels in the phosphatidylinositol fraction of HepG2 cells from 15.9% to 7.0%.[3]

(Rac)-FK 480 可用于研究癫痫或焦虑症。

Butabindide (UCL-1397) 是三肽肽酶II (TPP II)的选择性抑制剂，对 TPP I 和TPP II 的Ki 值分别为 10 μM 和 7 nM。Butabindide 抑制 TPP II 以保护 CCK-8 免于失活。

Snf 8906 is a CCK-8 analog.

DA-3934 has a high affinity for gastrin/CCK-B receptors and high selectivity over CCK-A receptors. DA-3934 and its methyl ester derivative inhibited pentagastrin-induced gastric acid secretion in rats in a dose-dependent manner.

Devazepide is a competitive and orally active nonpeptide antagonist of cholecystokinin (CCK) receptor (IC50s: 81 pM, 45 pM, and 245 nM for rat pancreatic, bovine gallbladder and guinea pig brain CCK receptors, respectively).

Dexloxiglumide, an active enantiomer of Loxiglumide, inhibits smooth muscle cell contractions induced by cholecystokinin-octapeptide (CCK-8). It is a selective antagonist of cholecystokinin type A (CCKA) receptors.

Cholecystokinin (26-33) free acid 是胆囊收缩素 (CCK) 的一部分， 是脊椎动物中枢神经系统中存在的 CCKB 型受体的高选择性配体，可诱导大鼠轻度味觉厌恶条件反射。

[Thr28, Nle31]-Cholecystokinin (25-33) 是一种具备CCK8所有生物活性的胆囊收缩素 (CCK) 类似物，表现出食欲抑制功效。它在胃肠道系统和中枢神经系统中担任激素和神经递质角色。此肽通过 Thr28 和 Nle31 的特殊替代，展现出在酸性条件下的高稳定性，并能抵抗空气氧化（防止蛋氨酸受损）。其主要构象特征为以Thr4为核心的γ转角和Gly5分隔的C末端螺旋片段。

Ceruletide Ammonium acetate (FI-6934 Ammonium acetate) 是一种胆囊收缩素 (CCK) 受体激动剂。它是一种安全有效的胆囊动力剂和小肠和胰腺外分泌兴奋剂。

Jmv 332 is a cyclic analog of the C-terminal hexapeptide of CCK. It is a CCK gastrin receptor agonist.

Jmv 176 is a CCK agonist when first given and becomes a cholecystokinin antagonist after 3-4 hours.